A Ten-Week Study Evaluating The Effectiveness And Safety Of Zoloft In Children And Adolescents With A Diagnosis Of PTSD

This study has been terminated.
(Please see Detailed Description below for termination reason.)
Sponsor:
Information provided by:
Pfizer
ClinicalTrials.gov Identifier:
NCT00150306
First received: September 6, 2005
Last updated: August 16, 2007
Last verified: August 2007
  Purpose

To evaluate the safety and efficacy of sertraline compared to placebo in children and adolescents (6 to 17 years of age) who are outpatients with Posttraumatic Stress Disorder.


Condition Intervention Phase
Stress Disorders, Post-Traumatic
Drug: Zoloft (Sertraline)
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Multicenter, 10-Week, Randomized, Double-Blind Study Of Sertraline And Placebo In Children And Adolescents With Posttraumatic Stress Disorder (PTSD)

Resource links provided by NLM:


Further study details as provided by Pfizer:

Primary Outcome Measures:
  • The primary efficacy parameter is the University of California at Los Angeles Post-Traumatic Stress Disorder Index for DSM-IV (UCLA PTSD-I).

Secondary Outcome Measures:
  • Secondary efficacy measures include
  • Child Stress Disorder Checklist (CSDC)
  • Clinical Global Impression Severity (CGI-S)
  • Clinical Global Impression Improvement (CGI-I)
  • Children's Depression Rating Scale - Revised edition (CDRS-R)

Estimated Enrollment: 160
Study Start Date: November 2002
Study Completion Date: July 2007
Detailed Description:

This study was terminated on July 11, 2007. The results of the primary endpoint analysis at the interim showed that the Zoloft group was not significantly different than the placebo on the primary endpoint and therefore the decision was made to terminate the trial. The decision to terminate the trial was not based on any safety concerns.

  Eligibility

Ages Eligible for Study:   6 Years to 17 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects must be from 6 to 17 years of age and will have a maximum age of 17 at the Baseline Visit of the study.
  • Subjects must have a diagnosis of Posttraumatic Stress Disorder as defined by DSM-IV and determined by the Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL).

Exclusion Criteria:

  • Subjects whose trauma is ongoing, or who are living in the same home as their abuser, or who are expected to participate in litigation related to their trauma during the course of the study will be excluded from participation.
  • Subjects who are likely to or are at high risk for experiencing re-exposure to their index trauma.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00150306

  Hide Study Locations
Locations
United States, Arizona
Pfizer Investigational Site
Scottsdale, Arizona, United States, 85281
United States, California
Pfizer Investigational Site
Sacramento, California, United States, 95817
Pfizer Investigational Site
San Diego, California, United States, 92111
Pfizer Investigational Site
San Marcos, California, United States, 92078
United States, District of Columbia
Pfizer Investigational Site
Washington, District of Columbia, United States, 20010
United States, Florida
Pfizer Investigational Site
Gainesville, Florida, United States, 32611
United States, Indiana
Pfizer Investigational Site
Indianapolis, Indiana, United States, 46202-5200
Pfizer Investigational Site
Terre Haute, Indiana, United States, 47802
United States, Kansas
Pfizer Investigational Site
Overland Park, Kansas, United States, 66214
United States, Louisiana
Pfizer Investigational Site
Baton Rouge, Louisiana, United States, 70816
Pfizer Investigational Site
New Orleans, Louisiana, United States, 70112
United States, Maryland
Pfizer Investigational Site
Bethesda, Maryland, United States, 20814
United States, Nevada
Pfizer Investigational Site
Las Vegas, Nevada, United States, 89128
United States, New Hampshire
Pfizer Investigational Site
Lebanon, New Hampshire, United States, 03756-0002
United States, New York
Pfizer Investigational Site
Manhasset, New York, United States, 11030
Pfizer Investigational Site
New York, New York, United States, 10016
Pfizer Investigational Site
Stony Brook, New York, United States, 11794
United States, Ohio
Pfizer Investigational Site
Cleveland, Ohio, United States, 44106
Pfizer Investigational Site
Lyndhurst, Ohio, United States, 44124
United States, South Carolina
Pfizer Investigational Site
Charleston, South Carolina, United States, 29425
United States, Texas
Pfizer Investigational Site
Galveston, Texas, United States, 77555-0188
Pfizer Investigational Site
Houston, Texas, United States, 77058
Pfizer Investigational Site
Plano, Texas, United States, 75024
Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
No publications provided by Pfizer

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00150306     History of Changes
Other Study ID Numbers: A0501061
Study First Received: September 6, 2005
Last Updated: August 16, 2007
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Disease
Stress Disorders, Traumatic
Stress Disorders, Post-Traumatic
Pathologic Processes
Anxiety Disorders
Mental Disorders
Sertraline
Antidepressive Agents
Psychotropic Drugs
Central Nervous System Agents
Therapeutic Uses
Pharmacologic Actions
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Serotonin Agents
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on September 18, 2014